Michael Gorton, Teladoc Founder, Recuro CEO Co-Authors Book with Jay Sanders, MD, Father of Telemedicine: Digital Medical Home – Telemedicine Ignites Creation of Precision Health
DALLAS–(BUSINESS WIRE)–Recuro Health (Recuro), an integrated digital health solutions company that transitions the U.S. healthcare system from a reactive, disease-focused model to a population health, outcomes approach, announces the publication of Digital Medical Home: How the Telemedicine Revolution Ignited the Creation of Precision Health, co-authored by Michael Gorton, founder of Teladoc and chief executive officer of Recuro Health, and Jay Sanders, MD, acknowledged as the “Father of Telemedicine” and founding board member and president emeritus of the American Telemedicine Association. Now available in print and digital formats, including Kindle, the book shares legendary stories, personal anecdotes and true accounts of the telemedicine revolution, including ongoing efforts to bring telehealth to mainstream America and documenting the power of fortitude combined with technology to spawn today’s virtual care solutions embodied in Recuro’s Digital Medical Home™.
“This has been a remarkable journey for those of us who pioneered the healthcare transformation to telemedicine, an incredible innovation which dramatically improved access to quality care at lower cost for millions worldwide,” says Gorton, noting additional contributions to the book by Michael Brombach, chief operating officer of Recuro Health, and Teladoc co-founder G. Byron Brooks, EE, MD. “It has been an honor to collaborate with Dr. Brooks and to co-author this book with a legend like Dr. Sanders. We worked diligently to create a definitive piece of literature that chronicles the extraordinary development of a game-changer for the entire healthcare industry.”
The authors recognize that telemedicine is finally mainstream. It will serve as the spark which ignites the creation of precision or personalized health and virtual care designed to catch medical issues before they become dangerous and expensive.
“I cannot think of two authors better qualified to tell the history of telemedicine,” says Bernard A Harris, MD, MBA, FACP, former NASA astronaut who conducted the first telemedicine conference from space with the Mayo Clinic and became the first African American to walk in space. “A sometimes-harrowing tale of the development of this industry, the most important part covers what’s next for all of us. Brilliant job!”
Dr. Sanders is CEO of The Global Telemedicine Group, adjunct professor of medicine at Johns Hopkins School of Medicine and is credited with the development of the first statewide telemedicine system; the first correctional telemedicine program; the first tele-homecare technology, called “The Electronic House Call,” and the first telemedicine kiosk. His consulting activities included NASA, DOD, HHS, the FCC, state governments, WHO and multiple academic institutions and Fortune 500 companies. Dr. Sanders is a graduate of Harvard Medical School, magna cum laude; a member of AOA; and did his residency at the Massachusetts General Hospital, where he was chief medical resident.
Dr. Sanders says, “Publication of this book is testimony to the legions of pioneers, especially Michael Gorton, who worked tirelessly to bring modern-day telehealth, better known as virtual care, to people wherever they are located and whenever needed. As today’s most in-demand healthcare innovation, virtual care solutions are improving quality of life for patients in every corner of the world, successfully meeting the primary care needs of an exploding population and addressing complex medical realities amid pressures to improve access and reduce costs.”
Gorton is a quintessential entrepreneur, mentor and company builder. He leads the Recuro Health team which includes several leaders from Teladoc, where he served as the founding CEO and pioneered an industry-changing health care model that created a new efficiency paradigm in healthcare. Ernst & Young LLP (EY US) recently named Gorton as one of the 2022 Entrepreneurs Of The Year® based upon his entrepreneurial spirit, purpose, growth and impact, among other core contributions and attributes.
About Recuro Health
Recuro is an integrated digital health solutions company with a uniquely personalized, holistic and proactive approach to virtual health. Recuro’s Digital Medical Home™ enables easy connectivity to virtual care, including primary and urgent care, behavioral health, at-home lab testing, genomics testing, as well as a suite of supplemental benefits spanning pharmacy, care management and care navigation all on one platform. www.recurohealth.com
To view the original press release, click here.
AscellaHealth Ranked Number 238 Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500™
BERWYN, Pa.–(BUSINESS WIRE)–AscellaHealth today announced it ranked 238 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 28th year. AscellaHealth grew 640% during this three-year period from 2018 to 2021.
AscellaHealth’s president and chief executive officer, Dea Belazi, credits the organization’s tremendous growth with its single-source, end-to-end solutions that tighten the specialty pharmacy (SP) value chain and its focus on optimizing access to expensive specialty and rare disease medications which result in improved patient outcomes. He said, “The AscellaHealth team is honored to share the spotlight with such exceptional companies and we are extremely gratified to earn this distinction. AscellaHealth is proud to offer custom solutions to pharmaceutical manufacturers and other stakeholders that enhance the lives of specialty and rare disease patients throughout the country and globally.”
“As the past year has shown us, innovation in important areas such as life sciences is critical to addressing infectious disease and other global health issues,” said Paul Silverglate, vice chair, Deloitte LLP and U.S. technology sector leader. “In addition, technology must keep pace with ever-changing consumer and corporate demands for faster, safer and more efficient solutions to new societal challenges. Each year I am in awe of the immense talent the Technology Fast 500 rankings reveal, confirming the winners’ relentless pursuit of creativity and their ability to solve real-world problems that benefit us all.”
“This year’s Technology Fast 500 list is a true reflection of some of today’s most determined and inspiring pioneers who have prospered by anticipating what’s next, understanding what’s needed to succeed and driving creativity forward,” said Christie Simons, partner, Deloitte & Touche LLP and industry leader for technology, media and telecommunications within Deloitte’s audit and assurance practice. “Representing all facets of technology, the winners have shown they not only have the vision but can also expertly manage their companies through rapid growth. We congratulate each winner on their impressive achievements.”
AscellaHealth previously ranked 299 as a Technology Fast 500™ award winner for 2021.
Overall, 2022 Technology Fast 500™ companies achieved revenue growth ranging from 241% to 125,138% from 2018 to 2021, with median growth of 611%.
About the 2022 Deloitte Technology Fast 500™
Now in its 28th year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies — both public and private — in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2018 to 2021.
In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues. Companies must have base-year operating revenues of at least US$50,000, and current-year operating revenues of at least US$5 million. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.
About AscellaHealth LLC
AscellaHealth is a global Healthcare & Specialty Pharmacy solutions organization serving patients, payers, life sciences manufacturers and providers, offering a comprehensive portfolio of customized, tech-enabled specialty pharmaceutical and personalized medical management services. A multiple Inc. 5000 winner and NASP 2022 Strategic Channel Partner of the Year award winner, AscellaHealth’s unique, patient-centric approach is built upon proprietary technology processes for innovative programs and services optimizing health outcomes and quality of life for patients with complex chronic conditions or rare diseases that require specialty medications and/or gene and cell therapies. Most recently, AscellaHealth has joined with its subsidiaries, Optime Care and Terebellum to form the AscellaHealth Family of Companies. Visit www.AscellaHealth.com.
About Deloitte
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as “Deloitte Global”) does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the “Deloitte” name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.
To view the original press release, click here.
Guideway Care Ranked Number 47th Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500™
Attributes 3,518% revenue growth to its unique care guidance model of resolving non-clinical and clinical barriers to patient care through a health equity approach
BIRMINGHAM, Ala.–(BUSINESS WIRE)–Guideway Care today announced it ranked 47th on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 28th year.
Guideway Care’s chief executive officer, Craig Parker, credits its tech-enabled, human interaction care guidance model, and Guideway team members’ dedication to improving patient lives through a health equity approach, with the company’s 3,518% revenue growth. He said, “It is an honor to be selected by Deloitte for this prestigious award among a distinguished group of finalists.”
“As the past year has shown us, innovation in important areas such as life sciences is critical to addressing infectious disease and other global health issues,” said Paul Silverglate, vice chair, Deloitte LLP and U.S. technology sector leader. “In addition, technology must keep pace with ever-changing consumer and corporate demands for faster, safer and more efficient solutions to new societal challenges. Each year I am in awe of the immense talent the Technology Fast 500 rankings reveal, confirming the winners’ relentless pursuit of creativity and their ability to solve real-world problems that benefit us all.”
“This year’s Technology Fast 500 list is a true reflection of some of today’s most determined and inspiring pioneers who have prospered by anticipating what’s next, understanding what’s needed to succeed and driving creativity forward,” said Christie Simons, partner, Deloitte & Touche LLP and industry leader for technology, media and telecommunications within Deloitte’s audit and assurance practice. “Representing all facets of technology, the winners have shown they not only have the vision but can also expertly manage their companies through rapid growth. We congratulate each winner on their impressive achievements.”
Overall, 2022 Technology Fast 500™ companies achieved revenue growth ranging from 241% to 125,138% from 2018 to 2021, with median growth of 611%.
About the 2022 Deloitte Technology Fast 500™
Now in its 28th year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies — both public and private — in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2018 to 2021.
In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues. Companies must have base-year operating revenues of at least US$50,000, and current-year operating revenues of at least US$5 million. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.
About Guideway Care
For more than 10 years Guideway has delivered a proven, scalable technology-enabled Service as a Solution for advancing health equity in Value-Based Care. Partnering with hospitals/health systems, payers and provider organizations, Guideway reduces health disparities, improves patient/member satisfaction and lowers total cost of care. Highly trained Care Guides, supported by a proprietary technology platform, build peer-to patient relationships that allow for the identification and resolution of non-clinical and clinical barriers to accessing quality care. By maximizing the patient care experience and resolving barriers that lead to avoidable deterioration and acute care utilization, the Guideway approach to patient activation creates value for all stakeholders. www.guidewaycare.com
About Deloitte
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as “Deloitte Global”) does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the “Deloitte” name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.
To view the original press release, click here.
Understanding the Link Between NAFLD and Diabetes: Echosens Points to New AACE Guideline Supporting FibroScan as Key Component of Type 2 Diabetes Management
Echosens Recognizes November 2022 American Diabetes Month, Urges Non-invasive Detection, Monitoring of Liver Fat and Stiffness
WALTHAM, Mass.–(BUSINESS WIRE)–Echosens North America, a high-technology company offering the FibroScan® portfolio of solutions, recognizes the importance of American Diabetes Month this November for bringing greater attention to the value of non-invasive technology, such as FibroScan, to measure and monitor liver stiffness and detect nonalcoholic fatty liver disease (NAFLD). According to the American Association of Clinical Endocrinology (AACE), the risk of NAFLD, a common co-morbidity of Type 2 diabetes, is two-to-threefold higher in individuals with Type 2 diabetes mellitus and/or obesity but can be halted or reversed if detected in its earliest stages.
These new guideline recommendations as reported in AACE reinforce the use of FibroScan solutions for the management of patients with NAFLD throughout the patient care continuum. The recommendations are a breakthrough in early diagnosis and management of patients with NAFLD, targeting primary care and endocrinology clinical settings.
“American Diabetes Month is an ideal opportunity to highlight this new guideline which includes 34 evidence-based clinical practice recommendations for the screening, diagnosis, and management of adults and children with NAFLD and/or NASH,” says Jon Gingrich, CEO, Echosens, North America. “Left undiagnosed, these conditions can be difficult to control, making early interventions more important than ever in helping individuals introduce lifestyle changes that can slow disease progression.”
AACE recommendations related to FibroScan include:
- Liver stiffness measurement by vibration controlled transient elastography (LSM by VCTE) should be used for further workup in individuals that are in the “high-risk” group who have an indeterminate or high FIB-4 score.
- LSM by VCTE is preferred as it can quantify liver fibrosis and liver fat with controlled attenuation parameter (CAP) for risk stratification in one test.
- LSM by VCTE is best validated to identify advanced disease and predict liver-related outcomes.
“Fortunately, with a diagnostic confirmation, lifestyle changes and continued care, individuals can integrate diet and exercise programs that effectively reduce liver fat and improve glucose control, which are consistent with approaches used for diabetes care,” says Gingrich. “American Diabetes Month demonstrates an effective public health outreach effort to increase awareness and advocacy for patients touched by diabetes and other related diseases.”
Global incidence of NAFLD is increasing and is estimated to affect 32.4% of the world’s population according to a 2022 study, with men more likely than women to develop it (39.7% vs. 25.6%). Approximately 70% of persons with T2D have NAFLD (steatosis), and approximately 15% have clinically significant liver fibrosis (stages ≥ F2). Additionally, prevalence rates of NASH are significantly higher in those with T2D and visceral obesity, affecting approximately 30% to 40% of persons with diabetes and between 25% and 30% of those with obesity. Type 2 diabetes mellitus and NAFLD frequently co-exist in patients and share the same pathophysiological manifestations, including hepatic steatosis and fibrosis. Left untreated, NAFLD can progress to nonalcoholic steatohepatitis (NASH), a more serious and complex condition that can lead to the development of cirrhosis and the need for a liver transplant.
FibroScan is a painless, non-invasive exam that assesses and monitors liver stiffness to detect NAFLD in its earliest stages, even when the individual is asymptomatic. As a non-invasive diagnostic tool recognized worldwide and validated in over 3,500 peer-reviewed publications and 160 international guidelines, including American Gastroenterological Association (AGA), American Association of Clinical Endocrinology (AACE) and American Heart Association (AHA), FibroScan uses LSM by VCTE and CAP to provide a high degree of diagnostic accuracy for liver steatosis that can be performed at the point-of-care. Based upon the FibroScan results, further assessments, such as painful or expensive liver biopsies, can be avoided.
About Echosens
Echosens, the developer of FibroScan®, is an innovative high-technology company offering a full range of products and services supporting physicians in their assessment and management of patients with chronic liver diseases. FibroScan is supported by over 3,500 peer-reviewed publications and 160 international guidelines. Examinations are covered by Medicare, Medicaid and many insurance plans. For more information, please visit https://www.echosens.com/.
To view the original press release, click here.
Why the U.S. is among the 5 worst countries for employee benefits
By Paola Peralta
benefitnews.com — In recent years, U.S. companies have had to fight for employee attention and affection, and many organizations have expanded their benefits offerings to appeal to the workforce. But has it been enough?
International insurance provider William Russell recently released its list of the best and worst countries for workers when it comes to guaranteed employee benefits.
To view the article in its entirety, click here.
Hidden audits reveal millions in overcharges by Medicare Advantage plans
By Fred Schulte & Holly K. Hacker
npr.org — Newly released federal audits reveal widespread overcharges and other errors in payments to Medicare Advantage health plans, with some plans overbilling the government more than $1,000 per patient a year on average.
Summaries of the 90 audits, which examined billings from 2011 through 2013 and are the most recent reviews completed, were obtained exclusively by KHN through a three-year Freedom of Information Act lawsuit, which was settled in late September.
To view the article in its entirety, click here.
Treating Long Covid Is Rife With Guesswork
By Blake Farmer, Nashville Public Radiokhn.org —Medical equipment is still strewn around the house of Rick Lucas, 62, nearly two years after he came home from the hospital. He picks up a spirometer, a device that measures lung capacity, and takes a deep breath — though not as deep as he’d like.
Still, Lucas has come a long way for someone who spent more than three months on a ventilator because of covid-19.
To view the article in its entirety, click here.